In reaction to Pfizer’s announcement of voluntary licenses of its COVID-19 oral antiviral treatment Paxlovid to the Medicines Patent Pool, People’s Vaccine Alliance spokesperson and Oxfam America’s Senior Advocacy Advisor, Robbie Silverman, said: “Pfizer’s announcement to voluntarily licence the COVID treatment Paxlovid is welcome but is far from enough."
